Whole Cell Bacterin Veterinary Vaccine Development

Whole cell bacterin veterinary vaccines consist of inactivated cells from one or multiple bacterial strains. These vaccines are not subjected to antigen purification, leading to the generation of immunity against a wide range of bacterial constituents. As a result, antibodies developed in response to the vaccine effectively counteract the pathogens and combat the associated infections. BioVenic offers whole cell bacterin vaccine development services to assist you from every angle, from strain culture to formulation development, making animals fight off bacterial infections.

Our Services

Media Optimization

The development of whole cell bacterin vaccines requires a large number of bacteria in a physiologically active state. Therefore, suitable nutrient media that provide the right biochemical environment and maintain all the characteristics of the microorganisms are required for vaccine development applications. Considering efficiency, safety and cost, researchers develop their own proprietary media formulations for large-scale production and procurement. BioVenic provides personalized service support to help you develop your customized media formulations to maximize the potential of your bacterial lines and vaccines.

Fig.1 Optimized service flow for media commissioning. (BioVenic Original)

Inactivation

The development involves a variety of methods to achieve pathogen inactivation, including both chemical methods and physical techniques. Chemical methods include the use of agents such as formaldehyde, ethylene oxide and acetoethylenimine to inactivate pathogens while maintaining their ability to stimulate an immune response. Similarly, physical methods such as gamma-irradiation and electron-beam-irradiation cause DNA damage or mutation of the pathogen, rendering it non-functional. BioVenic offers a wide range of inactivators and inactivation methods according to your whole cell bacterin vaccine research and development needs.

Adjuvant Development

Whole cell bacterin veterinary vaccines are inactivated, and an unintended consequence of this operation is the loss of immunogenicity, which necessitates the addition of substances that enhance immunogenicity. Adjuvants can be used to enhance the immunogenicity of these purified vaccines without significantly increasing reactogenicity. BioVenic offers adjuvant development services to enhance the immunogenicity of your vaccines through the modification of existing adjuvant compositions, and the exploration of novel vaccine adjuvants, including cytokine adjuvant, propolis adjuvant and adjuvants derived from microorganisms.

Whole Cell Bacterin Veterinary Vaccine Development Services

BioVenic is not only committed to the development of highly effective whole cell bacterin veterinary vaccines, but also emphasizes comprehensive assessments of safety and efficacy. Our extensive in vivo and in vitro testing ensures that vaccine candidates have excellent immunogenicity and protection. Our team is proficient in manufacturing techniques to ensure vaccine stability and consistency.

To learn more about BioVenic's comprehensive services, please visit the links below.

• In Vitro Assays
• In Vivo Assays
• Contract Manufacturing

BioVenic provides reliable bacterial inactivation services to ensure the efficacy of whole cell bacterin veterinary vaccines. In addition to inactivation, we also provide formulation optimization services, whether it is bacterial media or vaccine adjuvants, the above optimization services improve the efficacy of vaccines for livestock, poultry, companion animals, aquaculture species and more. Please contact us for further information on whole cell bacterin veterinary vaccine research and development.